There is a pressing need to capture and track subtle cognitive change at the preclinical
stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in
2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild …

In older adults with normal cognition, cognitive reserve (CR) is known to be associated with
the neuropsychological profile. We investigated the association between comprehensive CR …

This study aimed to determine associations between modifiable dementia risk factors
(MDRF), across domains mood symptomatology, lifestyle behaviors, cardiovascular …

Introduction Alzheimer's disease and related dementias (ADRD) represent a substantial
global public health challenge with multifaceted impacts on individuals, families, and …

Introduction Sensitive neuropsychological tests are needed to improve power for clinical
trials in early Alzheimer's disease (AD). Methods To develop a neuropsychological …

Introduction We aimed to define a Mayo Preclinical Alzheimer's disease Cognitive
Composite (Mayo‐PACC) that prioritizes parsimony and use of public domain measures to …

Early diagnosis is crucial to treatment success. This is especially relevant for Alzheimer's
disease (AD), with its protracted preclinical phase. Most health care systems do not have the …